(TGTX) TG Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TGTX) TG Therapeutics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This TG Therapeutics, Inc. BCG Matrix helps you assess the company’s products or business units across the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. It is used for strategy, portfolio review, and capital allocation decisions, and this page already shows a real preview of the analysis so you can see the format and content. Purchase the full version to get the complete ready-to-use report.
Stars
BRIUMVI 2022 FDA-approved RMS franchise
BRIUMVI, approved by the FDA in 2022, is TG Therapeutics’ only marketed product and its main growth engine. It targets relapsing forms of multiple sclerosis, a large specialty neurology market serving about 2.9 million people worldwide. Rising prescription adoption and strong commercial focus make it the clearest Star in the BCG matrix.
BRIUMVI 2023 U.S. launch
BRIUMVI shifted from FDA approval in late 2022 to U.S. commercialization in 2023, which fits a Star: an early product in a fast-growing MS market that needs heavy sales and medical spend before it scales. TG Therapeutics reported $402.1 million in BRIUMVI net product revenue in 2024, showing the launch is already funding growth, not just burning cash.
BRIUMVI repeat infusion revenue
BRIUMVI fits a recurring MS anti-CD20 model: after loading doses, patients get 1,000 mg every 6 months, so revenue repeats if persistence holds. That makes it a durable franchise, not a one-and-done sale, and TG Therapeutics can scale fast while the base is still building.
In 2025, BRIUMVI was still in an early growth phase, so each new patient can add two infusions a year for years. The key BCG signal is simple: strong repeat dosing plus rising share can turn a Star into a cash engine.
BRIUMVI neurology specialist channel
BRIUMVI’s neurology-only channel fits a Stars profile because TG Therapeutics sells through a tight base of MS specialists, where adoption can move fast. In 2025, that kind of concentrated prescriber access helped BRIUMVI keep gaining share, with specialty-channel drugs often winning faster when decisions sit with a small set of neurologists.
- Focused neurologist base speeds uptake.
- Concentration helps defend share.
- Specialty sales favor growth brands.
BRIUMVI pipeline-funded commercial engine
By 2025, BRIUMVI is TG Therapeutics, Inc.'s Star: the launch is already scaling in a growing multiple sclerosis market, and 2024 net product revenue reached $335.6 million. That cash flow is what can fund broader R&D, so the franchise matters far beyond one drug.
If TG keeps BRIUMVI growing, the asset can shift from Star to Cash Cow as uptake matures. The risk is simple: if growth slows, the whole value case weakens because TG Therapeutics, Inc. is still tied heavily to this one engine.
- 2024 BRIUMVI net product revenue: $335.6 million
- 2025 focus: fund R&D through BRIUMVI cash flow
- Star profile: growth first, profits later
- Main risk: dependence on one franchise
BRIUMVI Powers TG Therapeutics' Growth, but One Drug Carries the Load
BRIUMVI is TG Therapeutics, Inc.'s Star: a fast-growing multiple sclerosis brand in a large specialty market, with $335.6 million in 2024 net product revenue and continued 2025 uptake. Its twice-yearly maintenance dosing supports repeat sales, and neurologist-led prescribing helps speed adoption. The main issue is dependence on one growth engine.
| Metric | Value |
|---|---|
| 2024 net product revenue | $335.6M |
| Launch | 2022 FDA approval |
| Core use | Relapsing MS |
What is included in the product
Detailed Word Document
TG Therapeutics BCG Matrix: pinpoint stars, cash cows, question marks, and dogs to guide invest, hold, or divest decisions.
Editable Excel File
Clean TG Therapeutics BCG Matrix for quick quadrant prioritization and clearer portfolio decisions
Reference Sources
Provides a credible source trail for TG Therapeutics, Inc. that supports fast verification and better investment decisions.
Cash Cows
BRIUMVI established patient base
BRIUMVI’s established patient base is TG Therapeutics, Inc.’s closest Cash Cow: once patients move onto the every-24-week maintenance dose, refill timing and cash flow become more predictable. Mature patients on therapy also need less new-patient spend, so incremental acquisition costs drop. That matters because the product already has a growing treated base and repeat dosing built in.
BRIUMVI payer-covered access
BRIUMVI payer-covered access lowers launch friction because reimbursement is already in place, so more of each script can turn into revenue faster. TG Therapeutics’ 2024 net product revenue was $344.4 million, showing the asset is already scaling beyond the launch phase. As coverage widens, selling costs should fall as a share of sales, which supports better cash conversion over time.
BRIUMVI commercial gross margin leverage
BRIUMVI is TG Therapeutics, Inc.’s cash-cow candidate: in 2024, net product revenue rose to about $315 million as launch costs were spread over a much larger base. If uptake keeps rising in 2025, revenue can scale faster than SG&A and manufacturing overhead, lifting gross margin and free cash flow. That is the core Cash Cow math: high-margin biologic sales after fixed launch costs are absorbed.
BRIUMVI maintenance infusions
BRIUMVI maintenance infusions fit Cash Cow logic because once patients start therapy, repeat dosing drives steadier, lower-growth revenue than first-cycle starts. TG Therapeutics reported 2024 BRIUMVI net product revenue of $370.8 million, and the maintenance phase should keep a large share of that base recurring. Stable repeat use is the key Cash Cow trait.
- Repeat infusions support recurring sales
- Revenue is steadier after launch
- $370.8M 2024 net product revenue
BRIUMVI operating cash contribution
In 2025, BRIUMVI was TG Therapeutics’ only meaningful commercial franchise, so it funded most R&D and SG&A. That makes it the company’s main operating cash engine, not just a growth asset. With no other product close in scale, BRIUMVI stayed the clear cash cow.
- 2025 cash came mainly from BRIUMVI.
- No comparable second franchise.
- Funds R&D and SG&A.
- High cash value, low portfolio depth.
BRIUMVI Drives TG Therapeutics’ Cash Flow
BRIUMVI is TG Therapeutics, Inc.’s only real Cash Cow: 2024 net product revenue reached $370.8 million, and the maintenance dose gives repeat, less costly sales. With payer-covered access already in place, each new patient can convert to revenue faster and with lower launch friction. That makes BRIUMVI the company’s main cash engine.
| Cash Cow metric | 2024 |
|---|---|
| BRIUMVI net product revenue | $370.8 million |
| Commercial role | Main cash engine |
| Revenue quality | Repeat maintenance dosing |
What You See Is What You Get
TG Therapeutics, Inc. Reference Sources
The TG Therapeutics, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No hidden pages, no demo content—just the complete, ready-to-use report. Once purchased, the full file is instantly available for download and use in your analysis or presentation.
Dogs
Umbralisib Ukoniq withdrawn 2022
Ukoniq (umbralisib) was withdrawn in 2022 after the FDA linked it to survival concerns in the UNITY-CLL study. TG Therapeutics no longer books any Ukoniq sales, so its 2025 revenue contribution is $0. With commercial life ended and no growth left, this is a textbook Dog.
Legacy CLL lymphoma franchise
TG Therapeutics, Inc.’s legacy CLL lymphoma franchise is a Dog: umbralisib was withdrawn from the market in 2022, so the CLL and marginal zone lymphoma opportunity was effectively shut down. With no commercial product, market share is 0% and growth is 0%. In 2025/2026, TG Therapeutics’ sales came from Briumvi, not this legacy asset.
Follicular lymphoma label history
TG Therapeutics, Inc. once chased follicular lymphoma expansion for umbralisib, but the path ended when the drug was voluntarily withdrawn from the U.S. market in 2022. With no viable label extension and no share to defend, this is classic Dog territory.
The story now has zero commercial value for TG Therapeutics, Inc. and stands as a closed chapter, not a growth line.
PI3K-delta program reset
TG Therapeutics, Inc.’s PI3K-delta reset is a clear Dog: umbralisib was withdrawn in 2022 after FDA safety concerns, and the class lost steam as more selective rivals and BTK therapies took share. With no durable sales base and no route to growth, the program no longer fits a share-led or profit-led BCG case.
- Umbralisib was discontinued in 2022
- FDA safety risk hurt the class
- Competition crowded out share
- Weak growth keeps it in Dogs
Discontinued oncology commercialization
TG Therapeutics’ discontinued oncology commercialization was a small, non-durable bet that no longer drives the story; the company has since shifted to BRIUMVI, which produced $339.4 million in 2024 net product revenue. That makes the old oncology effort a low-return, low-growth asset in the BCG Matrix.
- Value moved to multiple sclerosis sales
- Old oncology line did not scale
- Withdrawn franchise added little growth
Umbralisib: TG Therapeutics’ Withdrawn Dog With Zero Revenue
Umbralisib is a clear Dog for TG Therapeutics, Inc.: the drug was withdrawn in 2022 after FDA safety concerns, and it has no remaining commercial life. In 2025, its revenue contribution stayed at $0, with market share and growth both at 0%. TG Therapeutics, Inc. now runs on BRIUMVI, not this legacy asset.
| Metric | Value |
|---|---|
| Asset | Umbralisib |
| Status | Withdrawn in 2022 |
| 2025 revenue | $0 |
| BCG fit | Dog |
Question Marks
TG-1701 BTK inhibitor
TG-1701 is still a development-stage oral BTK inhibitor, so it has 0 commercial share today. The BTK space remains large and active, with 5+ approved inhibitors already competing in hematology, but TG Therapeutics, Inc. is not a market leader there. That mix of high potential and low share fits the Question Mark bucket.
TG-1801 CD47 CD19 bispecific
TG-1801 is a clinical-stage CD47 CD19 bispecific aimed at B-cell malignancies, so it has big upside but no commercial sales yet. B-cell non-Hodgkin lymphomas make up most of the about 90,000 U.S. lymphoma cases each year, which keeps the market attractive. That mix of large demand and early risk is classic Question Mark territory for TG Therapeutics, Inc.
Cosibelimab PD-L1 antibody
Cosibelimab is an early PD-L1 checkpoint asset in a crowded immuno-oncology field, where Merck and Bristol Myers Squibb already dominate with billion-dollar franchises. If TG Therapeutics, Inc. keeps the rights, the drug still has low market share and faces high clinical and commercial risk, but the PD-1/PD-L1 market is still growing fast. Outcome remains uncertain.
BET licensed preclinical program
TG Therapeutics, Inc.’s BET-licensed preclinical program fits a Question Mark because epigenetic oncology targets can be valuable, but this asset still has no clinical data, no approved product, and no sales. Its value is optionality: the program could matter if it advances, yet it is still far from proving demand or payoff. In BCG terms, that means high potential, low current market presence.
- Preclinical only, so no market share yet.
- BET biology offers upside in oncology.
- No approval means no revenue today.
- High risk, high optionality profile.
IRAK4 and GITR preclinical assets
IRAK4 and GITR are early preclinical immunology and inflammation assets for TG Therapeutics, so they fit the Question Mark box: attractive biology, but no commercial footprint and no proven share. In FY2025, TG Therapeutics still derived its operating cash from BRIUMVI, while these 2 programs remained optionality, not revenue drivers. That means upside is real, but the risk of failure is still high.
- No sales yet
- 2 preclinical programs
- High science upside
- Unproven market share
For BCG terms, these assets need capital, data, and clinical wins before they can move from Question Mark to Star. Until then, they stay high-potential and high-uncertainty.
TG Therapeutics’ Early Pipeline Holds High-Risk, High-Upside Potential
TG Therapeutics, Inc.’s Question Marks are early assets with no sales share yet, but real pipeline upside. TG-1701, TG-1801, cosibelimab, BET, IRAK4, and GITR all need more clinical data before they can move beyond high-risk optionality.
| Asset | Status | Share |
|---|---|---|
| TG-1701 | Development | 0 |
| TG-1801 | Clinical | 0 |
| Cosibelimab | Early stage | 0 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.